Boston Scientific Corp.
Here’s whether Boston Scientific Corp. (BSX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-0.86% over 10 days); RSI 85 — overbought, elevated pullback risk; weak 1-year return of -50.2%. Currently 52.7% off its 52-week high. Score: -4/7.
BSX is trading below its 200-day MA ($70.67) — a key warning sign the longer-term trend is under pressure. With an RSI of 84.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -50.2% compares to +20.4% for SPY (trailed the market by 70.6%). The current 52.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.